Casgevy

by | Jan 30, 2024 | Blog, MHRA, NHS

The MHRA is the first Regulatory body in the world to authorise a Crispr-based gene therapy. Casgevy has been authorised for patients over twelve years old who suffer from beta-thalassaemia and sickle cell disease and for whom haematopoietic stem cell transplantation is an appropriate treatment, but a suitable donor is not available. The MHRA approval sets a president in the UK, and the NHS innovative medicine fund should pave the way for eligible patients to receive a treatment for their often painful and life-threatening disease.

Testimonials

Pharmacy Consulting has been performing consultancy work for Vygon for several years, during that time they have provided us with a very professional and efficient service. PCL helped Vygon obtain their original Wholesale Dealers Licence and have provided Responsible Person  (RP) support to our Quality Team ever since.  PCL guided us successfully through our MHRA inspection. More recently, Jackie delivered GDP update training sessions for me and my deputy when I started in my new role as Head … Read more
Testimonial from Vygon